BOSTON, Nov. 6, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF), today announced completion of enrollment in the Company's global, multicenter, randomized, placebo-controlled, 28-day, Phase 2 study evalua

WALTHAM, Mass., Nov. 6, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the first patient has been dosed in AUGMENT-101, a Phase 1/2 clinical trial evaluating SNDX-5613, Syndax's potent, highly sel

SMITHS FALLS, ON, Nov. 5, 2019 /PRNewswire/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX: WEED) (NYSE: CGC) will release its financial results for the second quarter fiscal 2020 ended September 30, 2019 before financial markets open on November 14, 2019.

TEL AVIV, Israel, Nov. 6, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today it will release its unaudited financial results for the quarter ended September 30, 2019 on Monday, November 11, 2019, before the US mark

TEL AVIV, Israel, Nov. 6, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral SCD1 modulator currently in a Phase 3/4 clinical trial for the treatment of nonalcoholic steatohepatitis ("NASH") and fibrosis provides today a busi

KFAR SABA, Israel, Nov. 6, 2019 /PRNewswire/ -- Following the AnapnoGuard™ airway management system's FDA market clearance at the end of 2018, Hospitech Respiration announced that a new article was recently published by physicians from

CARLSBAD, Calif., Nov. 6, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported its financial results for the third quarter and year-to-date 2019 and recent business highlights.

REHOVOT, Israel, Nov. 6, 2019 /PRNewswire/ -- Canonic, a wholly owned subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN) focused on the development of medical cannabis products, announces today the initiation of its cultivation and breeding program of cannabis varieties with unique genomic profiles for the development of medical cannabis products. The ini

ALPHARETTA, Ga., Nov. 6, 2019 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today announced that Dave Crawford, vice president of investor relations, will present at the Stephens Nashville Investment Conference at the Omni Nashville hotel in Nashville, TN on Wednesday, Nov. 13

AUSTIN, Texas, Nov. 6, 2019 /PRNewswire/ -- Beginning Nov. 1 through Dec. 15, Ambetter from Superior HealthPlan wil